Degenhard Marx

USPTO Granted Patents = 15 (Patent Applications = 2)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 17 (Patent Applications = 13)

Average Co-Inventor Count = 5.6

ph-index = 2

Forward Citations = 12(Granted Patents)

Location History:

Constance, DE (2016)
Moos, DE (2009 - 2017)

Company Filing History:

Years Active: 2009-2017

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9713614 - Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases (2017-07-25),

2. 9340522 - Pyrazolone-derivatives and their use as PDE-4 inhibitors (2016-05-17),

3. 9090597 - Pyrazolone derivatives as PDE4 inhibitors (2015-07-28),

4. 9018175 - 3,4,4a,10b-Tetrahydro-1H-thiopyrano-[44,3-c] isoquinoline derivatives (2015-04-28),

5. 8865745 - Pyrazolone derivatives as PDE4 inhibitors (2014-10-21),

6. 8648100 - Roflumilast for the treatment of pulmonary hypertension (2014-02-11),

7. 8609848 - Pyrazolone-derivatives and their use as PDE-4 inhibitors (2013-12-17),

8. 8486923 - Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis (2013-07-16),

9. 8445501 - Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines (2013-05-21),

10. 8304436 - Pyrazolone derivatives as PDE4 inhibitors (2012-11-06),

11. 8258124 - Combination medicament (2012-09-04),

12. 7879833 - Combination medicament (2011-02-01),

13. 7879832 - Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis (2011-02-01),

14. 7838521 - 3-oxa-10-aza-phenanthrenes (2010-11-23),

15. 7589205 - 3-thia-10-aza-phenanthrene derivatives (2009-09-15),

Title: Degenhard Marx: A Trailblazer in Pharmaceutical Innovations

Introduction

Degenhard Marx, a prominent inventor based in Moos, Germany, has made remarkable contributions to the field of pharmaceuticals. With an impressive portfolio of 15 patents, his work primarily focuses on innovative treatments for inflammatory diseases. His inventions have significantly advanced therapeutic options available for patients.

Latest Patents

Among his latest patents, Degenhard Marx has developed a groundbreaking combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases. This invention concerns the combined use of a PDE4 inhibitor and a HMG-CoA reductase inhibitor, aiming to enhance both prevention and treatment efficacy for patients suffering from these conditions. Another notable patent involves pyrazolone-derivatives, identified as novel effective inhibitors of the type 4 phosphodiesterase, which promise to further bolster therapeutic strategies against related ailments.

Career Highlights

Degenhard Marx has made significant strides during his career, working with established pharmaceutical companies such as Takeda GmbH and Nycomed GmbH. His contributions in these firms have been instrumental in driving research and development efforts forward, leading to innovative solutions in the pharmaceutical industry.

Collaborations

Throughout his career, Degenhard has collaborated with esteemed colleagues, including Armin Hatzelmann and Christof Zitt. Together, they have pursued various research projects, enhancing the scope and impact of their work in the field.

Conclusion

Degenhard Marx's work exemplifies the spirit of innovation in the pharmaceutical sector. His patents not only reflect his expertise but also hold the potential to transform patient care for those with inflammatory diseases. As he continues to develop groundbreaking therapies, his role as an inventor remains pivotal in advancing medical science.

This text is generated by artificial intelligence and may not be accurate.